Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1HWR

MOLECULAR RECOGNITION OF CYCLIC UREA HIV PROTEASE INHIBITORS

1HWR の概要
エントリーDOI10.2210/pdb1hwr/pdb
分子名称HIV-1 PROTEASE, [4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO-5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7-BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE (2 entities in total)
機能のキーワードaspartyl protease, hydrolase, acid proteinase
由来する生物種Human immunodeficiency virus 1
細胞内の位置Gag-Pol polyprotein: Host cell membrane; Lipid-anchor . Matrix protein p17: Virion membrane; Lipid- anchor . Capsid protein p24: Virion . Nucleocapsid protein p7: Virion . Reverse transcriptase/ribonuclease H: Virion . Integrase: Virion : P04585
タンパク質・核酸の鎖数2
化学式量合計21921.85
構造登録者
Chang, C.-H. (登録日: 1998-03-20, 公開日: 1999-03-23, 最終更新日: 2024-05-22)
主引用文献Ala, P.J.,DeLoskey, R.J.,Huston, E.E.,Jadhav, P.K.,Lam, P.Y.,Eyermann, C.J.,Hodge, C.N.,Schadt, M.C.,Lewandowski, F.A.,Weber, P.C.,McCabe, D.D.,Duke, J.L.,Chang, C.H.
Molecular recognition of cyclic urea HIV-1 protease inhibitors.
J.Biol.Chem., 273:12325-12331, 1998
Cited by
PubMed Abstract: As long as the threat of human immunodeficiency virus (HIV) protease drug resistance still exists, there will be a need for more potent antiretroviral agents. We have therefore determined the crystal structures of HIV-1 protease in complex with six cyclic urea inhibitors: XK216, XK263, DMP323, DMP450, XV638, and SD146, in an attempt to identify 1) the key interactions responsible for their high potency and 2) new interactions that might improve their therapeutic benefit. The structures reveal that the preorganized, C2 symmetric scaffolds of the inhibitors are anchored in the active site of the protease by six hydrogen bonds and that their P1 and P2 substituents participate in extensive van der Waals interactions and hydrogen bonds. Because all of our inhibitors possess benzyl groups at P1 and P1', their relative binding affinities are modulated by the extent of their P2 interactions, e.g. XK216, the least potent inhibitor (Ki (inhibition constant) = 4.70 nM), possesses the smallest P2 and the lowest number of P2-S2 interactions; whereas SD146, the most potent inhibitor (Ki = 0.02 nM), contains a benzimidazolylbenzamide at P2 and participates in fourteen hydrogen bonds and approximately 200 van der Waals interactions. This analysis identifies the strongest interactions between the protease and the inhibitors, suggests ways to improve potency by building into the S2 subsite, and reveals how conformational changes and unique features of the viral protease increase the binding affinity of HIV protease inhibitors.
PubMed: 9575185
DOI: 10.1074/jbc.273.20.12325
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.8 Å)
構造検証レポート
Validation report summary of 1hwr
検証レポート(詳細版)ダウンロードをダウンロード

239492

件を2025-07-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon